CytoSorbents Corporation to Showcase Innovations at H.C. Wainwright 27th Annual Global Investment Conference

CytoSorbents Corporation to Present at H.C. Wainwright 27th Annual Global Investment Conference

CytoSorbents Corporation (NASDAQ: CTSO), a pioneering player in the medical field focused on the treatment of life-threatening conditions within the intensive care unit and cardiac surgery, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will take place at the prestigious Lotte New York Palace Hotel on September 8, 2025.

Conference Details

The management team will be presenting the company’s innovative technologies and engaging in one-on-one meetings with potential investors, marking an important opportunity to highlight CytoSorbents' efforts in revolutionizing blood purification methods.

- Date: September 8, 2025
- Time: 11:30 AM ET
- Live Webcast Link: H.C. Wainwright / CytoSorbents

For those unable to attend, a replay of the presentation will be available for up to 90 days after the event.

About CytoSorbents Corporation

Established with the aim of addressing serious medical conditions, CytoSorbents specializes in blood purification technologies that are essential for managing critical patients in hospital settings. Their proprietary blood purification systems utilize biocompatible polymer beads designed to effectively extract harmful substances from blood and body fluids, a process instrumental during various critical medical procedures.

CytoSorbents' flagship product, CytoSorb®, is already approved in the EU and is distributed across over 70 countries worldwide. To date, the company has successfully implemented nearly 300,000 devices, underlining the widespread recognition of its contributions to healthcare.

CytoSorb technology is particularly significant in two areas: 1) Surgical Procedures: During cardiothoracic operations, the system helps in clearing blood thinners, thus minimizing the risk of excessive bleeding. 2) Inflammatory Illnesses: It addresses various severe illnesses such as sepsis, burn injuries, and multiple organ failures, showcasing its critical role in saving lives by mitigating the effects of severe inflammation.

Expanding Horizons

The company continues to innovate by developing additional products, including DrugSorb™-ATR, which aims to reduce surgical bleeding caused by anticoagulant medications. Although currently under review by the FDA for approval, DrugSorb-ATR represents a significant advancement in managing surgical risks effectively.

In 2024, CytoSorbents also received FDA Breakthrough Device Designations for their new systems intended to facilitate the safety of high-risk surgeries further. The recent inquiries with the FDA and Health Canada regarding the commercial authorization of their products reflect CytoSorbents' commitment to improving medical standards through evidence-based advancements.

Looking Ahead

Despite facing challenges concerning regulatory submissions, including a recent denial by the FDA regarding a marketing approval request, CytoSorbents remains optimistic about collaborating with health authorities to clarify routes for market entrance.

By participating in important forums like the H.C. Wainwright Conference, CytoSorbents not only strengthens its visibility in the investment community but also reiterates its mission to innovate and enhance treatment options available to critically ill patients.

For more information about CytoSorbents Corporation and its innovative products, visit their official website. Follow them on social media to stay updated with their latest advancements.

Conclusion

CytoSorbents Corporation’s commitment to tackling life-threatening conditions through blood purification methods is a testament to their role as industry leaders in this crucial sector. Their participation in significant investment conferences is a strategic move to solidify investor confidence and attract potential partnerships that can further their mission. As they navigate challenges and developments, the future looks promising for both the company and those whose lives they aim to improve.